Ty. Chao et al., EXPRESSION OF EPSTEIN-BARR VIRUS-ENCODED RNAS AS A MARKER FOR METASTATIC UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA, Cancer, 78(1), 1996, pp. 24-29
BACKGROUND. Epstein-Barr virus (EBV) is associated with undifferentiat
ed nasopharyngeal carcinoma (NPC). EBV-encoded nonpolyadenylated RNAs
(EBERs) are often used as a marker to detect EBV-infected NPC cells. T
his study was conducted to document the expression and determine the s
ignificance of EBERs in NPC cells at various metastatic sites. METHODS
. An in situ hybridization (ISH) technique was used to identify the pr
esence of EBERs in paraffin embedded tissues of primary and metastatic
sites obtained from 21 patients with NPC. Nineteen of these patients
had undifferentiated lesions, and 2 had squamous cell carcinoma. One h
undred and fifty specimens of normal tissues and tissues from patients
with a variety of benign and malignant diseases other than NPC served
as controls. In the NPC specimens, the expression of latent membrane
protein (LMP) and a lytic protein, BZLF-1, were also examined by immun
ohistochemistry. RESULTS. Tissues from all patients with undiffferenti
ated NPC and one patient with squamous cell carcinoma contained EBERs
in the malignant cells; the other case of squamous cell carcinoma was
negative. In metastatic NPCs, LMP was expressed in 18% (4 of 22) of ti
ssues whereas BZLF-1 was not expressed in any tissues. EBERs were not
detected in the 43 patients with normal tissues and benign lesions. In
malignant diseases other than NPC, EBERs were detected in only 2 of 1
2 cases of non-Hodgkin's lymphoma, 1 of 2 cases of Hodgkin's lymphoma,
and 1 of 6 cases of gastric cancer. CONCLUSIONS. By virtue of the dir
ect correlation between latent EBV infection and NPC, the authors conc
lude that EBERs can be used as a sensitive marker to identify NPC cell
s at various metastatic sites by techniques of in situ hybridization,
and that demonstration of EBERs in lesions of undifferentiated histolo
gy may be useful as a diagnostic adjunct for NPC presenting as metasta
tic cancer of unknown origin.